Table 2.
Disease characteristics at the index visit
| Disease characteristic | Mean (SD) or n (%) N = 130 |
|---|---|
| Psoriasis presentation and duration | |
| History of psoriasis morphologya, n (%) | |
| Guttate | 2 (1.5) |
| Erythrodermic | 4 (3.1) |
| Pustular (localized) | 0 (0.0) |
| Pustular (generalized) | 0 (0.0) |
| Inverse/intertriginous | 7 (5.4) |
| Scalp | 41 (31.5) |
| Nail | 13 (10.0) |
| Palmoplantar | 12 (9.2) |
| Psoriasis duration (years), mean (SD) | 17.5 (13.4) |
| Psoriasis patients with PsA | |
| PsA, dermatologist-diagnosed, n (%) | 48 (37.2) |
| PsA, diagnosis confirmed by rheumatologist, n (%) | 25 (19.2) |
| PsA duration (years), mean (SD) | 10.9 (11.7) |
| PEST Score, n (%) | |
| 0 | 44 (34.1) |
| 1 | 25 (19.4) |
| 2 | 26 (20.2) |
| 3 | 15 (11.6) |
| 4 | 13 (10.1) |
| 5 | 6 (4.7) |
| PEST score of 3+ , n (%) | 34 (26.4) |
| Psoriasis treatment characteristics | |
| Concomitant psoriasis therapy, n (%) | |
| GUS + systemic therapy | 9 (6.9) |
| GUS + topical agents | 55 (42.3) |
| GUS + phototherapy | 3 (2.3) |
| Biologic experienceb, n (%) | |
| Biologic naïve | 27 (20.8) |
| 1 previous biologic agent received | 29 (22.3) |
| ≥ 1 previous biologic agent received | 103 (79.2) |
| ≥ 2 previous biologic agents received | 74 (56.9) |
| Systemic therapy experiencec,d, n (%) | |
| Systemic naïve | 15 (11.5) |
| 1 previous systemic agent received | 18 (13.9) |
| ≥ 2 previous systemic agents received | 97 (74.6) |
| Disease activity | |
| BSA (% involvement), mean (SD) | 12.4 (10.4) |
| BSA (% involvement), n (%) | |
| 0% to < 3% (mild) | 9 (6.9) |
| 3–10% (moderate) | 67 (51.5) |
| > 10% (severe) | 54 (41.5) |
| PASI Score (range: 0–72), mean (SD) | 9.9 (7.7) |
| PASI Score > 10, n (%) | 53 (40.8) |
| IGA Score, mean (SD) | 3.0 (0.6) |
| IGA Score, n (%) | |
| 2 (mild) | 26 (20.0) |
| 3 (moderate) | 80 (61.5) |
| 4 (severe) | 24 (18.5) |
| Patient-reported outcome measures | |
| DLQI Score (range: 0–30), n | 130 |
| Mean (SD) | 8.0 (6.0) |
| DLQI “Effect on Life,” n (%) | |
| 0–1 (none) | 13 (10.0) |
| 2–5 (small) | 38 (29.2) |
| 6–10 (moderate) | 41 (31.5) |
| 11–20 (very large) | 32 (24.6) |
| 21–30 (extremely large) | 6 (4.6) |
| WPAI summary scores (range: 0–100%) | |
| Currently employed, n (%) | 97 (74.6) |
| % Work hours missed due to PsO,e n | 90 |
| Mean (SD) | 4.4 (15.7) |
| % Impairment while working due to PsO,e n | 88 |
| Mean (SD) | 17.7 (24.5) |
| % Work hours affected by PsO,e n | 85 |
| Mean (SD) | 19.0 (25.7) |
| % Daily activities affected by PsO, n | 128 |
| Mean (SD) | 22.7 (27.3) |
| Patient health state today (EQ-VAS, range: 0–100), n | 130 |
| Mean (SD) | 73.4 (19.7) |
| Patient global assessment (range: 0–100), n | 130 |
| Mean (SD) | 50.4 (27.7) |
| Patient fatigue assessment (VAS, range: 0–100), n | 129 |
| Mean (SD) | 33.9 (30.1) |
| Patient skin pain assessment (VAS, range: 0–100), n | 130 |
| Mean (SD) | 34.9 (32.2) |
| Patient itch assessment (VAS, range: 0–100), n | 130 |
| Mean (SD) | 54.1 (33.5) |
BSA body surface area, DLQI Dermatology Life Quality Index, GUS guselkumab, IGA Investigator’s Global Assessment, PASI Psoriasis Area Severity Index, PEST Psoriasis Epidemiology Screening Tool, PSA psoriatic arthritis, PsO psoriasis, SD standard deviation, VAS visual analog scale, WPAI Work Productivity Activity Impairment
aAll subjects included in this report had a diagnosis of plaque psoriasis. Additional morphologies present in this population are summarized in this section
bPrior biologics count does not include subject’s current biologic. No patients had previously received GUS
cPrior non-biologic systemic use count does not include the current non-biologic systemic therapy, if applicable
dPatients in the non-biologic users group were biologic naïve
eEvaluated among currently employed patients